

J 11 38. A method according to claim 37, wherein said compound is administered at a dosage of 0.5-60 mg/kg of body weight per day.

J 12 39. A method according to claim 38, wherein said compound is administered at a dosage of 1-20 mg/kg of body weight per day.

J 40. A method according to claim 37, wherein said composition further comprises another antiviral agent.


41. A method according to claim 40, wherein said antiviral agent is an acyclic nucleoside, an interferon, a renal excretion inhibitor, a nucleoside transport inhibitor, a 2',3'-dideoxynucleoside, an immunomodulator, erythropoietin, amphotericin, thymopentin, foscarnet, ribavirin, or an inhibitor of HIV binding to CD4.

42. A method according to claim 37, wherein said mammal is a human.

### REMARKS

As the Examiner is aware, the instant application is co-pending with continuation application Serial No. 08/460,854. For the sake of clarity, the claims in the instant application have been amended so as to be directed to methods of use. Conversely, the claims in the co-pending continuation application are now directed to pharmaceutical compositions.

Respectfully submitted,



Brian P. Heaney (Reg. No. 32,542)  
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Boulevard, Suite 1400  
Arlington, Virginia 22201  
Direct Dial: 703-812-5308  
Facsimile: 703-243-6410  
Internet Address: heaney@mwzb.com

**Filed: August 3, 1998**

K:\PAT\IAFG\14\US\SuppAmend 7-98.wpd